Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

Speciality: Oncology

Description:

A warm welcome to all the medical professionals in this interesting session on the front-line management of ALK-positive Lung Cancer. 

The frontline management of ALK+ NSCLC has undergone a paradigm shift over the last decade, with the introduction of targeted therapies. The discovery of the EML4 fusion gene and the subsequent development of crizotinib in 2011 have significantly improved personalized medicine for ALK-mutated non-small cell lung cancer. The recent data from the CROWN trial further supports the use of lorlatinib as a first-line treatment option for ALK+ NSCLC, with a significant improvement in progression-free survival compared to other ALK inhibitors.

The CROWN trial demonstrated that lorlatinib has a higher intracranial response rate and better CNS progression-free survival than other ALK inhibitors. This suggests that lorlatinib is particularly effective in managing brain metastases, common in ALK+ NSCLC. These findings highlight the importance of considering lorlatinib as the first-line treatment option for ALK+ NSCLC patients with brain metastases.

Therefore,  get an overall knowledge regarding the management of ALK+ NSCLC. Listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.

See More Webinars @ Hidoc Webinars